Table 4 Synoptic review of randomized controlled trials and real-life experiences using erenumab as a preventive treatment for migraine
Study | Study design | Type of patients | Preventive medications | Previous treatment failures | Main findings for erenumab compared with controls |
|---|---|---|---|---|---|
Tepper et al. (2017) NCT02066415 [49] | Randomized, double-blind, placebo-controlled, phase 2 trial | Chronic migraine | Not allowed | < 3 (no response) | MMD reduced by 6.6 days vs. 4.2 days with placebo. 40% vs. 41% in the erenumab 70 mg vs. 140 mg groups achieved a > 50% reduction |
Dodick et al. (2018) ARISE [50] | Randomized, double-blind, placebo-controlled, phase 3 study | Episodic migraine | Allowed | < 2 (no response) | MMD reduced by 2.9 days vs. 1.8 days with placebo. 39.7% of erenumab recipients achieved ≥50% reduction |
Goadsby et al. 2017 STRIVE [51] | Randomized, double-blind, placebo-controlled, phase 3 study | Episodic migraine | Allowed (< 2) | < 2 (no response) | MMD reduced by 3.2 vs. days in the erenumab 70 mg vs. 140 mg group, and by 1.8 days with placebo. 43.3%, 50.0%, and 26.6%, respectively, achieved a ≥ 50% reduction in MMD |
Ashina et al. (2018) [52] | Randomized, double-blind, placebo-controlled study with subgroup analyses | Chronic migraine | Not allowed | 0, ≥1, ≥2 (no response) | Reduction in MMD vs. placebo for erenumab 70 mg vs. 140 mg: No prior treatment failure, 2.2 vs. 0.5 days; ≥1 prior failed medication category subgroup, 2.5 vs. 3.3 days; ≥2 prior failed medication categories, 2.7 vs. 4.3 days |
Reuter et al. (2018) LIBERTY [48] | Randomized, double-blind, placebo-controlled, phase 3b study | Episodic migraine | Not allowed | Failure of 2–4 prior preventive treatments | MMD reduced by > 50% in 30% of patients |
Barbanti et al. (2019) [18] | Real-life data | Episodic and chronic migraine | Allowed | Failure of 4–6 prior preventive treatments | ≥50% reduction of MMD at weeks 4 and 8, respectively, in 68.2% and 87.5% of chronic patients and 50% and 100% of episodic patients |
Ornello et al. (2020) [19] | Real-life data | Episodic and chronic migraine | Allowed | Failure of ≥2 prior preventive treatments | MMD reduced from a mean of 19 days to 4 days. MMD reduced by > 50% in 70% of patients |
Raffaelli et al. (2020) [20] | Retrospective real-life | Chronic migraine | Not specified | Failure of 5 prior preventive treatments plus onabotulinumtoxinA | MHD reduction of 3.7 days after the first treatment and 4.7 days after 3 treatment cycles |
Robbins et al. (2020) [53] | Retrospective real-life | Chronic migraine | Allowed | Failure of ≥3 prior preventive treatments | MMD reduced by > 30% in 43% of patients |